Olopatadine plus mometasone for seasonal allergic rhinitis treatment: A pooled analysis of clinical trials.

Braz J Otorhinolaryngol · 2026 · PMC13096916 · PMID 41985293

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the difference in rTOSS in the phase II study did not reach statistical significance, 18 both phase III trials confirmed statistical superiority of Olo/Mom over placebo. 11 , 17 Olo/Mom versus olopatadine and mometasone This study showed that Olo/Mom significantly improved rTNSS, iTNSS, and RQLQ score compared to olopatadine and mometasone.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.